Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 220

Results For "Medica"

2721 News Found

Vestige launches Pre-Gluco Health capsules for the early prevention of diabetes
Healthcare | February 21, 2022

Vestige launches Pre-Gluco Health capsules for the early prevention of diabetes

According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic


Enhertu Phase III results to redefine how metastatic breast cancer is classifed
Biotech | February 21, 2022

Enhertu Phase III results to redefine how metastatic breast cancer is classifed

Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.


Resolution Therapeutics strengthens its team with two new appointments
People | February 20, 2022

Resolution Therapeutics strengthens its team with two new appointments

Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance


USFDA lifts clinical hold on submission of Covaxin
News | February 20, 2022

USFDA lifts clinical hold on submission of Covaxin

Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades


Moderna expands Its mRNA pipeline with new development programs
Biotech | February 20, 2022

Moderna expands Its mRNA pipeline with new development programs

These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.


Poxel’s PXL065 granted FDA fast track designation for X-linked adrenoleukodystrophy
Drug Approval | February 20, 2022

Poxel’s PXL065 granted FDA fast track designation for X-linked adrenoleukodystrophy

Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear


Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation
News | February 19, 2022

Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation

Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study


UAE to recognise Indian pharma products within three months
News | February 19, 2022

UAE to recognise Indian pharma products within three months

The agreement also had a permanent safeguard mechanism which can be resorted to in a situation of sudden surge in imports.


Arrowhead Pharmaceuticals initiates study of ARO-C3
News | February 19, 2022

Arrowhead Pharmaceuticals initiates study of ARO-C3

AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3


USFDA clears Kairos Pharma’s IND to treat prostrate cancer
Biotech | February 18, 2022

USFDA clears Kairos Pharma’s IND to treat prostrate cancer

Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope